COVID‐19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease‐Modifying Antirheumatic Drugs on Clinical Outcomes.
Leveraging the United States Epicenter to Provide Insights on COVID‐19 in Patients With Systemic Lupus Erythematosus.
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.
Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease.
KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease.
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.
Interleukin 1 receptor antagonist ( ) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease.
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.